Assess today's live Aimmune Therapeutics Inc (AIMT) share price, performance and insights using our live NASDAQ: AIMT stock exchange data. Analyse the historical data and Aimmune Therapeutics Inc ...

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

Children with low-risk peanut allergy who are referred for oral immunotherapy may be cleared of their allergy before starting ...

His career includes roles at Bristol-Myers Squibb, GlaxoSmithKline, ViiV Healthcare, Pfizer, and Aimmune Therapeutics. He has managed products through their full lifecycle, from pre-clinical ...

Treading new ground There is no FDA-approved therapy for peanut allergy in the one to three age group, although in 2020 the regulator cleared Aimmune Therapeutics’ oral immunotherapy Palforzia ...

Nestlé obtained Palforzia in August 2020 through its $2.6bn acquisition of Aimmune Therapeutics, the therapy’s original developer. Before the acquisition, Nestlé had invested $473m in Aimmune ...

Aimmune Therapeutics (NASDAQ:AIMT) initiated with Outperform rating and $64 (76% upside) price target by Robert Baird.Bluebird bio... BySeeking Alpha • Dec 21, 2017 Mustang Bio announces $12.8M ...

The global food allergy market is experiencing remarkable growth, projected to reach a valuation of USD 66.15 Billion by the end of 2033, expanding at a CAGR of 5.2% from its estimated value of USD 39 ...

It has been about a month since the last earnings report for Esperion Therapeutics (ESPR). Shares have lost about 15.8% in that time frame, underperforming the S&P 500. Will the recent negative ...

Claim your 7-day free trial now. Summit Therapeutics Inc SMMT stock is trading lower on Friday. On Thursday, Summit Therapeutics’ partner Akeso Inc. received the U.S. Food and Drug ...